MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
40.02
+1.69 (4.41%)
Apr 21, 2025, 4:00 PM EDT - Market closed
MLTX Employees
MoonLake Immunotherapeutics had 100 employees as of December 31, 2024. The number of employees increased by 50 or 100.00% compared to the previous year.
Employees
100
Change (1Y)
50
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$1,189,355
Market Cap
2.53B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
MLTX News
- 13 days ago - MoonLake Immunotherapeutics: A Buy At Dips - Seeking Alpha
- 18 days ago - MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates - GlobeNewsWire
- 7 weeks ago - MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
- 3 months ago - MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - GlobeNewsWire
- 8 months ago - MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewsWire
- 9 months ago - MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward - Seeking Alpha
- 1 year ago - MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa - GlobeNewsWire